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Abstract 
Background and Purpose: Imaging is frequently used to select acute stroke patients for intra-
arterial treatment (IAT). Quantitative cerebral blood flow (CBF) can be measured non-invasively 
with arterial spin labeling (ASL) magnetic resonance imaging (MRI). CBF levels in the 
contralateral (unaffected) hemisphere may affect capacity for collateral flow and patient outcome. 
The goal of this study was to determine whether higher contralateral CBF (cCBF) in acute stroke 
identifies patients with better 90-day functional outcome. 
 
Methods: Patients were part of the prospective, multicenter ‘Imaging Collaterals in Acute Stroke‘ 
(iCAS) study between 2013 and 2017. Consecutive patients were enrolled after being diagnosed 
with anterior circulation acute ischemic stroke. Inclusion criteria were ischemic anterior circulation 
stroke, baseline National Institutes of Health Stroke Scale (NIHSS)>=1, pre-stroke modified 
Rankin Score (mRS)<=2, onset-to-imaging-time (OIT) <24 hrs, with imaging including diffusion-
weighted imaging (DWI) and ASL. Patients were dichotomized into high and low cCBF groups 
based on median cCBF. Outcomes were assessed by day 1 and 5 NIHSS; and day 30 and 90 mRS. 
Multivariable logistic regression was used to test whether cCBF predicted good neurological 
outcome (mRS 0-2) at 90 days. 
 
Results:  Seventy-seven patients (41 female) met the inclusion criteria with median (inter-quartile 
range) age 66 (55-76) yrs, OIT 4.8 (3.6-7.7) hrs, and baseline NIHSS 13 (9-20). Median cCBF was 
38.9 (31.2-44.5) ml/100g/min. Higher cCBF predicted good outcome at day 90 (OR 4.6, 95% CI 
1.4-14.7, p=0.01), after controlling for baseline NIHSS, DWI lesion volume, and intra-arterial 
treatment.   
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Conclusion:  Higher quantitative contralateral CBF at baseline is a significant predictor of good 
neurological outcome at day 90. cCBF levels may inform decisions regarding stroke triage, 
treatment of acute stroke, and general outcome prognosis. 
 
Clinical Trial Registration:  
Imaging Collaterals in Acute Stroke (iCAS), unique identifier: NCT02225730, clinical trial 
registration URL: https://clinicaltrials.gov/ct2/show/NCT02225730  
 
 
Abstract word count: 291/300  
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Introduction 
 
Following an acute vessel occlusion, perfusion of the ischemic penumbra is sustained by collateral 
flow. Evaluation of cerebral hemodynamics in the stroke-affected, ipsilateral hemisphere to 
identify appropriate patients for intra-arterial thrombectomy (IAT) is a common practice.1-4 To the 
best of our knowledge, no studies have investigated the predictive role of quantitative perfusion 
biomarkers in the contralateral, unaffected hemisphere.  Higher cerebral blood flow (CBF) in the 
contralateral hemisphere might be associated with a greater capacity to mobilize collateral flow to 
affected regions in the ipsilateral hemisphere or be a marker for better cardiac output, and thereby 
be associated with better neurological outcomes.  
 
Arterial spin labeling (ASL) MRI enables measurement of quantitative CBF without the need for 
contrast agents and can be acquired in the acute stroke setting.5 ASL differs from the more 
commonly-applied contrast-enhanced methods with MRI or CT perfusion-weighted imaging 
(PWI), which do not routinely provide quantitative CBF information, instead providing relative 
measurements.  Meanwhile, ASL is prone to underestimate CBF in ischemic regions due to 
prolonged arterial arrival times.6-8  However, these issues are less prevalent in the contralateral 
hemisphere, where there is usually no acute ischemic event or large vessel occlusion.  In this study, 
we hypothesized that the high contralateral CBF (cCBF) at the time of ischemic stroke is associated 
with better outcome. 
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Materials and Methods 
 
Study Design and Patient Selection 
The cohort is part of the ongoing observational, prospective, multi-center ‘Imaging Collaterals in 
Acute Stroke‘ (iCAS) study (unique identifier: NCT02225730, clinical trial registration URL: 
https://clinicaltrials.gov/ct2/show/NCT02225730). The iCAS study has been approved by the 
Institutional Review Board. Informed consent was obtained from all subjects. The data that support 
the findings of this study are available from the corresponding author upon reasonable request.  
 
Patients were enrolled between November 2013 and August 2017, after being diagnosed with an 
acute ischemic stroke at four participating sites: Stanford University (Stanford, CA, United States), 
University of Pittsburgh Medical Center (UPMC, Pittsburgh, PA, United States), Swedish Medical 
Center (Seattle, WA, United States), and Eden Medical Center (Castro Valley, CA, United States). 
Patients imaged <24 hrs from last seen well and who were considered for intra-arterial 
endovascular therapy of an anterior circulation occlusion were eligible.  Specific inclusion criteria 
for patients were (a) anterior circulation ischemic hemispheric stroke, (b) baseline National 
Institutes of Health Stroke Scale (NIHSS) >=1, (c) <24 hrs onset-to-imaging-time (OIT), (d) pre-
stroke mRS <=2, (e) age >=18 yrs, (f) technically adequate imaging including diffusion-weighted 
imaging (DWI) and ASL.  Exclusion criteria were (a) MRI contraindications and (b) pregnancy.  
If deemed appropriate by the treating clinicians, patients received intra-arterial therapy (IAT). 
 
Imaging Acquisition and Analysis 
Imaging was performed at either 1.5T (Signa, GE Healthcare, Milwaukee, WI, USA) or 3T (750w, 
GE Healthcare, Milwaukee, WI, USA). ASL scans included single-delay pseudocontinuous ASL9 
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with labeling duration (LD) = 1.45s, post-labeling delay (PLD) = 2.025s (at 1.5T); and a multi-
delay (5-delay) ASL with LD = 2s, PLD = 0.7, 1.275, 1.85, 2.425, and 3s (at 3.0T). Proton density 
(PD)-weighted images were collected for quantification. The ASL images were reconstructed with 
an interpolated resolution of 1.9x1.9x6mm³ (1.5T) or 1.9x1.9x4mm3 (3.0T). Isotropic DWI images 
were acquired with TR/TE 4000/77.5ms, b=1000 s/mm2 and spatial resolution of 0.9x0.9x5mm3. 
Infarct volume was calculated using RAPID software (version 4.5.1, iSchemaView, Menlo Park, 
CA, USA). 
 
For single-delay ASL, the CBF maps were quantified using the simplified equation from Alsop et 
al.5  For multi-delay ASL, arterial transit time (ATT) corrected CBF maps were generated from a 
kinetic signal model10 with assumed arterial and tissue T1 of 1.65s and 1.5s, respectively.  This was 
performed using an automated standardized script in MATLAB R2013b (version 8.2.0.701, The 
MathWorks, Inc., Natick, MA, USA) using SPM8 (Statistical Parametric Mapping, The Wellcome 
Trust Centre for Neuroimaging, University College London, UK). 
 
All perfusion and diffusion images were first registered to the T1-weighted structural scans and 
then registered and normalized to the Montreal Neurological Institute (MNI) template. The atlas’ 
standard gray matter mask was then applied. CBF values were extracted automatically in gray 
matter regions-of-interest at four supratentorial levels corresponding to those assessed as part of 
the Alberta Stroke Program Early CT Score (ASPECTS) system (Supplemental Figure I, please 
see http://stroke.ahajournals.org).  Mean contralateral CBF (cCBF) was calculated across all ROIs 
in the unaffected brain hemisphere. Additional analyses based on follow-up imaging and 
corresponding imaging outcome measures are reported in the Supplemental Material 
(Supplemental Methods, please see http://stroke.ahajournals.org). 
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Clinical Assessment 
Neurological outcome was assessed by using NIHSS and the modified Rankin Score (mRS) at 
several timepoints.  NIHSS was measured at baseline before any intervention (NIHSS baseline), at 
24 hrs (NIHSS day 1), and at day 5 or at discharge (NIHSS day 5).  mRS was assessed at day 30 
(mRS day 30) and day 90 (mRS day 90) either by telephone or clinical visit. The primary endpoint 
was good neurological outcome at day 90, defined as mRS day 90 <=2. Secondary analyses were 
performed for NIHSS day 1, day 5, and mRS day 30.  Any missing values for NIHSS and mRS 
were imputed with data from last available visit using the traditional last observation carried 
forward (LOCF) method as described in the approved iCAS study protocol. For deceased patients, 
worst-case values were assigned to all time points after death: NIHSS=42, mRS=6. We tracked the 
etiological subtype of acute ischemic stroke using the TOAST classification (Supplemental Table 
I , please see http://stroke.ahajournals.org).11  
 
Regression Model and Statistical Analysis 
The full cohort was divided into patients with cCBF above the median (‘high cCBF group’) and 
below the median (‘low cCBF group’). An adjusted multivariable logistic regression model was 
applied to investigate the relationship between cCBF group and good 90-day outcome. We 
controlled for the following factors, which were analyzed in a univariable analysis as potentially 
being relevant: baseline NIHSS, DWI lesion volume, and the use of IAT after imaging. 
 
Statistical analyses were performed using Stata version 15.1 (StataCorp LP, College Station, TX, 
USA). Results are reported as medians with interquartile ranges (IQR). Outcome differences were 
assessed with Mann-Whitney U (NIHSS) and Fisher’s exact test (mRS). All analyses were 2-sided; 
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level of significance was set to α<0.05. Regression results are presented for each variable 
including odds ratio (OR), p-value, and 95% confidence interval (95% CI).  
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Results 
 
Patient Population 
109 patients underwent MRI.  Of these, 32 were excluded for the following reasons:  poor image 
quality and/or motion artifacts (n=19), no ASL performed at baseline (n=7), pre-stroke mRS >=3 
(n=3), OIT >24hrs (n=1), baseline NIHSS=0 (n=1), and bilateral stroke (n=1). Seventy-seven (77) 
patients were included in the analysis (Table 1): 41 (53%) females, age 66 (55-76) yrs, OIT 4.8 
(3.6-7.7) hrs, baseline NIHSS 13 (9-20).  Sixty-nine (90%) were scanned at 3T and the rest at 1.5T.  
A total of 46 patients (60%) received tissue plasminogen activator (tPA) before the baseline MRI 
scan. Following the baseline MRI, 41 patients underwent IAT (53%); in 33/41 (80%) of those, the 
final Thrombolysis in Cerebral Infarction (TICI) score was 2b or 3.  When comparing cCBF values 
for single-delay (37.6 ml/100g/min, IQR 30.2-43.6) vs. multi-delay ASL (39.0 ml/100g/min, IQR 
31.8-44.5), there was no significant difference found (p=0.87).  There was also no difference in the 
fraction of patients in the high and low cCBF groups regarding ASL type (Supplemental Table II, 
please see http://stroke.ahajournals.org). 
 
Dichotomized cCBF  
There were no significant differences in the clinical baseline characteristics between high and low 
cCBF groups (Table 1).  In particular, there was no significant linear correlation between DWI 
lesion size and cCBF (Supplemental Figure II, please see http://stroke.ahajournals.org). Median 
NIHSS at baseline/day 1/day 5 for low and high cCBF groups was 13/14/11 and 13/6.5/4.5, 
respectively (Figure 1). While there was no significant difference at baseline, NIHSS was 
significantly different between groups on both day 1 (p=0.016) and day 5 (p=0.003). High cCBF 
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significantly predicted good clinical outcomes as assessed by mRS at day 90 (p=0.011) (Figure 2), 
with 55% of high cCBF patients in the mRS 0-2 group compared with only 26% for the low cCBF 
group. There was also a trend towards better outcome at day 30, but this was not statistically 
significant.  
 
 
Multivariable analysis 
The univariate analysis identified the variables high cCBF, baseline NIHSS, DWI lesion volume, 
and intra-arterial treatment as significant factors for outcome prediction. In the multivariable 
analysis, patients were roughly 5 times more likely to be in the good 90-day clinical outcome group 
rather than poor outcome group if they presented with high cCBF at baseline imaging (OR 4.6, 
95% CI 1.4-14.7, p=0.011), while controlling for other significant contributing factors (p<0.05): 
baseline NIHSS (p=0.015) and DWI lesion volume (p=0.014) (Table 2). Patients with good 
outcome had lower baseline NIHSS and smaller DWI lesion size compared to those with poor 
outcome. All patients with a DWI lesion volume >=66 ml (n=18, 23%) had poor 90-day outcome.  
Representative cases are shown in Figure 3. 
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Discussion 
 
In this study, we demonstrated that higher CBF in the contralateral hemisphere is a strong 
determinant of good 90-day clinical outcome. This quantitative parameter, cCBF, varied strongly 
among patients, showing that there are marked inter-individual differences in CBF in the unaffected 
brain during acute ischemic stroke.   
 
To quantify perfusion in acute stroke patients, MR- or CT-based bolus perfusion imaging is most 
commonly used, with a ratio between the affected and unaffected regions being a commonly 
reported metric.1, 12-15 For example, the recent DEFUSE-3 trial used a cutoff of 30% of CBF based 
on the unaffected regions as a measure of irreversibly infarcted tissue using CTP.1  However, this 
semi-quantitative approach neglects the fact that the CBF levels in non-affected regions may differ 
substantially between patients. Fully quantitative approaches may provide more information;5 for 
example, Harston et al. have reported absolute CBF values in the acute stroke setting when 
evaluating serial perfusion imaging and tissue fate prediction.16 Our results show, first, that there 
is a wide range of CBF in the contralateral hemisphere of stroke patients, which is in line with 
recent reports on patient-level mean cCBF.16 This is not entirely unexpected as it is well-known 
that baseline CBF varies widely in patients of similar age, even though the explicit reasons for 
these variations are poorly understood.17 When assessing patients using relative measures, this 
important information is lost, which could give insight into the patient’s cardiac output or ability 
of the brain to deliver collateral flow. Other alternatives for quantitative perfusion measurements 
are H215O water PET and xenon CT;18, 19  however, these approaches are difficult to implement in 
the acute settings, require radiation, and have high cost and personnel needs.  ASL MRI is 
becoming increasingly available and has already been applied in the acute stroke setting in several 
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prior studies.7, 14, 16, 20 While acquiring MRI in the acute stroke setting is often challenging, the 
WAKE-UP study showed that patients with unknown stroke onset profit from MRI and suggested 
general feasibility of MRI in an acute setting.21, 22 There are a few studies that propose CT and MR 
bolus perfusion can be used in a quantitative manner to measure CBF;23-25 however, this is still 
uncommon in clinical routine and has not been validated to the degree that ASL has. A comparison 
of ASL-cCBF with other imaging techniques related to blood flow, such as multiphase CT, would 
be valuable. 
 
Recently, Raza and Rangaraju reviewed different existing prognostic scores to evaluate acute 
ischemic stroke clinically before endovascular treatment.26 Looking at 10 different prognostic 
scores in acute ischemic stroke, the authors found a ceiling effect for the scores’ area under the 
curve (AUC) with a prognostic accuracy of 0.8.26 Only three scores included radiographic 
parameters additionally to traditional clinical information, either based on CT ASPECTS regional 
infarct lesion core (PRE score27, HIAT2 score28) or MRI DWI lesion core volume (SAD score29). 
After the introduction of the mismatch concept for MRI30 and its translation to CT13, 31, there are 
several reports on other promising imaging parameters12, 32, 33 and collaterals with good outcome.33-
35 While, however, predominately age, baseline NIHSS, CT ASPECTS, and MRI DWI lesion 
volume have been evaluated so far,27, 29, 36 no such model includes quantitative CBF, largely due 
to the historical challenges of implementing such methods in the acute setting. 
 
cCBF measurements could affect patient triage, therapy, and care at various different timepoints. 
High cCBF might represent a biomarker for underlying good overall health,37-39 sufficient cardiac 
output,40, 41 and/or capacity to provide good collateral flow.42, 43 While we do not intend to alter 
any treatment recommendations with this observational study, our results may point at a future role 
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of cCBF as an objective and quantitative biomarker for therapy stratification: Dichotomized cCBF 
could be utilized as treatment decision tool supporting clinicians in deciding which patients might 
be suitable for IAT. One possibility is that patients with high cCBF on baseline MRI might be 
appropriate for more aggressive treatment.  
 
Based on this study, we cannot assess the precise mechanism of why higher cCBF is associated 
with better outcomes; the size of the strokes and the baseline NIHSS scores were similar between 
the high and low cCBF groups. Potential causes of inter-individual baseline CBF levels are age, 
sex, end-tidal CO2 level, cerebral diaschisis, and white matter (WM) lesion burden due to small 
vessel disease.44-49 Older patients generally tend to show lower brain perfusion.37, 50-52 Younger 
women tend to have higher brain perfusion compared to postmenopausal women and men, possibly 
due to differences in hematocrit.44, 53  Another potential cause of higher cCBF could be higher 
arterial CO2 levels, as could occur in patients with concomitant lung disease.46 Unfortunately, we 
do not have information on CO2 levels for our patients.  However, if CO2 levels were increased in 
sicker patients due to lung disease, this would be unexpected to improve their prognosis, as was 
seen with higher cCBF.   
 
cCBF could also be affected by the presence of transhemispheric diaschisis, in which reduced 
afferent input to the contralateral hemisphere leads to depressed cCBF.54-56 A xenon CT study in 
acute stroke patients found that cCBF was about 35% lower than in age-matched normal subjects.47 
One argument against diaschisis as a cause of reduced cCBF in our cohort is the lack of relationship 
of DWI lesion size with cCBF, although it is still possible that it could reflect a broader network-
based effect. 
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Lower cCBF could also be related to small vessel ischemic disease (leukoaraiosis).48, 49, 57 Prior 
stroke studies have shown that a high burden of white matter lesions is an indicator for bad 
neurological outcome.58, 59  Small vessel disease leads to vascular dysfunction which then could 
result in CBF decrease and neuronal dysfunction. Our acute MR imaging protocol did not include 
fluid-attenuated inversion recovery (FLAIR) imaging, so we could not evaluate directly the role of 
leukoaraiosis on cCBF levels.  
 
There are several limitations to this study. First, the sample size is limited and 17% of otherwise 
eligible patients were excluded from the study, primarily due to patient motion which is common 
in the acute stroke setting.  Second, because of the prospective enrollment of patients in the iCAS 
study, studies were performed at different field strengths with slightly different ASL sequences 
(single vs. multi-delay), though this likely increases generalizability of the results.  There were no 
differences in the percentage of patients in each group with single- and multi-delay ASL, nor was 
there any difference in the mean values of CBF based on the ASL type.  Third, patients received 
different types of treatment (none/tPA/IAT/both). The study’s regression model included 
information on reperfusion for the 53% of patients who received an IAT after the initial MRI exam. 
While cCBF is available for all patients, this study cannot assess the extent of reperfusion and 
collateral circulation of patients who received no or only tPA treatment. Fourth, as expected, the 
acute DWI lesion volume at baseline had a large impact on outcome, though we found a strong 
effect of cCBF even when this was controlled for in our analysis. Fifth, we note that use of cCBF 
is not applicable in bilateral stroke because there is no unaffected hemisphere. Even the presence 
of large non-acute contralateral infarcts could confound the interpretation of cCBF, though 
excluding them from the analysis would be straightforward. Sixth, there was no systematic 
information recorded on the contralateral arterial vessel status at the cervical level; intracranial 
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MRA was available in 75/77 subjects and only 1 patient in the low cCBF group (cCBF 36.7 ml/100 
g/min) had a significant stenosis or occlusion (ICA occlusion). But since the cervical region was 
not imaged, we cannot determine whether stenosis or occlusion at the carotid bifurcation was 
associated with low cCBF. 
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Conclusion 
 
Quantitative contralateral CBF is a significant predictor of clinical outcome at 90 days. High cCBF 
predicts good outcome, even when controlled for baseline NIHSS, DWI lesion size, and intra-
arterial treatment. Quantitative CBF is a predictive measurement that may be valuable for acute 
stroke triage, treatment, and general outcome prognosis. 
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Figures and Figure Legends 
 
Figure 1. Boxplot diagram depicting NIHSS at baseline (BL), day 1, and day 5 for low and high 
cCBF groups. 
 
Legend: 
While there were no differences for NIHSS at baseline (p=0.28), the differences were significant 
between groups at day 1 (*p=0.016) and day 5 (**p=0.003). cCBF indicates contralateral cerebral 
blood flow; and NIHSS, National Institutes of Health Stroke Scale. 
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Figure 2. mRS outcome at day 30 and 90 stratified by dichotomized cCBF (low vs. high cCBF 
group). 
 
Legend: 
Patients with high cCBF were significantly more likely to have a good outcome at day 90 (Fisher’s 
exact test, p=0.011). There was a trend towards similar good outcomes at day 30, but this did not 
reach statistical significance (p=0.09). cCBF indicates contralateral cerebral blood flow; and mRS, 
modified Rankin Score. 
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Figure 3. Representative patient cases. 
 
Legend: 
A: 46 year-old female. Left-sided hemiplegia, partial facial drop with total gaze paralysis, moderate 
sensory loss, complete hemianopia, and profound hemi-neglect. Baseline NIHSS of 16, DWI lesion 
37 mL, cCBF 58.1 ml/100g/min. No tPA but IAT with successful reperfusion (TICI 2b). Day 90 
mRS = 2. B: 66 year-old male. Severe aphasia, partial facial paralysis, and bilateral hemianopia. 
Baseline NIHSS of 11, DWI lesion 0 ml, cCBF 28.3 ml/100g/min. Both, tPA and IAT with 
successful reperfusion (TICI 2c). Day 90 mRS = 4. CBF indicates cerebral blood flow; cCBF, 
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contralateral CBF; NIHSS, National Institutes of Health Stroke Scale; tPA, tissue plasminogen 
activator; IAT, intra-arterial therapy; TICI, thrombolysis in cerebral infarction; mRS, modified 
Rankin Score; ASL, arterial spin labeling; DWI, diffusion-weighted imaging; and FLAIR, fluid-
attenuated inversion recovery. 
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Table 1. Demographics and baseline imaging information. 
 
Variable Full cohort 
(n=77) 
High cCBF 
group (n=38) 
Low cCBF 
group (n=39) 
p; High vs. 
low cCBF  
Age, median (IQR), years 66 (55-76) 63 (56-78) 66 (54-76) 0.98 
Sex, female, No. (%) 41 (53) 23 (61) 18 (46) 0.26 
Onset-to-imaging time (OIT), 
median (IQR), hrs 
4.8 (3.6-7.7) 4.7 (3.2-7.7) 5.0 (4.3-7.0) 0.62 
DWI lesion volume, median 
(IQR), ml 
16.7 (6.1-51.2) 17.8 (6.4-49.7) 15.2 (5.4-67.9) 0.84 
NIHSS baseline, median (IQR) 13 (9-20) 13 (8-18) 13 (9-22) 0.28 
cCBF, median (IQR), 
ml/100g/min 
38.9 (31.2-44.5) 44.6 (41.6-50.8) 31.2 (28.0-35.0) <0.001* 
tPA therapy, No.(%) 46 (60) 20 (53) 26 (67) 0.25 
Intra-arterial therapy (IAT), No. 
(%) 
41 (53) 21 (64) 20 (51) 0.82 
TICI 2b-3 among all IAT, (%) 33/41 (80) 15/21 (71) 18/20 (90) 0.24 
 
* Statistically significant, p<0.05 
cCBF indicates contralateral cerebral blood flow; IQR, interquartile range; DWI, diffusion-
weighted imaging; NIHSS, National Institutes of Health Stroke Scale; tPA, tissue plasminogen 
activator; and TICI, thrombolysis in cerebral infarction. 
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Table 2. Univariate and multivariable analyses (logistic regression) for good outcome (mRS 0-2) 
using dichotomized cCBF groups while controlling for potential confounders. In the adjusted 
multivariable model, DWI lesion volume and baseline NIHSS were identified as significant 
contributing factors. 
 
 Univariate analysis (unadjusted) Multivariable analysis (adjusted)† 
Variable Odds ratio 95% CI p Odds ratio 95% CI p 
Age 0.98 0.95 - 1.02 0.31 --- --- --- 
Sex 0.72 0.30 - 1.85 0.52 --- --- --- 
Previous stroke 0.38 0.07 – 2.01 0.26 --- --- --- 
Onset-to-imaging-time (OIT) 0.96 0.82 - 1.12 0.61 --- --- --- 
NIHSS at baseline 0.86 0.80 - 0.92 <0.001* 0.89 0.81 - 0.98 0.015* 
DWI lesion volume 0.97 0.95 - 0.99 <0.001* 0.98 0.96 - 1.00 0.014* 
tPA therapy 1.11 0.44 – 2.84 0.82 --- --- --- 
Intra-arterial therapy (IAT) 2.73 1.05 - 7.12 0.04* 1.59 0.49 – 5.13 0.44 
TICI 2b - 3 2.00 0.40 – 9.97 0.40 --- --- --- 
High cCBF  
(>=39ml/100g/min) 
 
3.58 1.36 - 9.43 0.010* 4.56 1.41 - 14.73 0.011* 
 
* Statistically significant, p<0.05 
† Multivariable logistic regression model for high cCBF, adjusting for potential confounders 
(NIHSS at baseline, DWI lesion volume, and intra-arterial therapy) 
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mRS indicates modified Rankin Score; NIHSS, National Institutes of Health Stroke Scale; DWI, 
diffusion-weighted imaging; tPA, tissue plasminogen activator; TICI, thrombolysis in cerebral 
infarction; and cCBF, contralateral cerebral blood flow. 
